STC-15 (METTL3 inhibitor) ✔️

STORM Therapeutics

Confirmed correct on August 16, 2023 at ACS Fall National Meeting.

STC-15 (formerly STM3480) is a first-in-class oral inhibitor of METTL3 developed by STORM Therapeutics that is currently in phase 1 trials for the treatment of advanced cancers (NCT05584111).

METTL3 stands for N6-adenosine-methyltransferase 70 kDa subunit. Not sure how acronym for that works out…presumably the methyltransferase part.

This is the first compound I’m covering from a private company!